cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
However, most analyses indicate Tyrannosaurus, while slower than large modern terrestrial predators due to being far larger, was still faster than large hadrosaurs and ceratopsians. Most evidence suggests hunting behavior in Tyrannosaurus. The eye sockets of tyrannosaurs are positioned so that the eyes would point forward, giving them binocular vision slightly better than that of modern hawks. It is not obvious why natural selection would have favored this long-term trend if tyrannosaurs had been pure scavengers, which would not have needed the advanced depth perception that stereoscopic vision provides. In modern animals, binocular vision is found mainly in predators (though not all predators have well-developed binocular vision).
Despite the trial data failing to show improvements in bone density on QCT scans, its primary goal, there were improvements on DXA scans. In a September 2020 press release, Mereo said it was seeking to do a phase III trial in 2021, and had received a Rare Pediatric Disease (RPD) designation from the US Food and Drug Administration (FDA). Romosozumab, which is also a monoclonal antibody targeting sclerostin, is an approved drug in the US and EU for the treatment of osteoporosis. The pharmaceutical industry analyst Evercore has remarked that "it could wipe out setrusumab's economics", as romosozumab is priced more cheaply than a drug for a rare disease would be, claiming that it will be "vital" to Ultragenyx's profit margins to prove its setrusumab is more efficacious than romosozumab for OI. A clinical trial evaluating romosozumab's efficacy in OI began in September 2020 and as of September 2021 is ongoing. Ultragenyx predicts that its phase 2/3 trials for setrusumab will be completed in 2026.
Such designers included Dave McDermott, who initially ran the Sven Co-op website before becoming a developer of it. Fearon had planned from the onset to include support for cooperatively playing through Half-Life's single-player campaign within Sven Co-op, but this was hampered initially by how the game's engine transitions from map to map, and made it difficult to keep players together in the multiplayer approach. Ultimately, the team was able to work this out, and later added support for Half-Life's two expansions, Half-Life: Opposing Force, and Half-Life: Blue Shift. Around 2004, prior to the release of Half-Life 2, Fearon had been planning to release Sven Co-op on Steam, but didn't due to confusion between the Sven Co-op team and Valve. Further, Fearon and the team had started work on a Sven Co-op 2 in anticipation of using the Source engine from Half-Life 2. Though they had developed a large number of assets for the mod, they were hindered by the lack of the SDK, which had been pushed back along with the release of Half-Life 2. Many of the team members had started to move on to other projects, and Fearon found they lost too many key members to continue development. Around this point Fearon opted to leave the project, giving the project lead over to Josh Polito. McDermott and Polito began negotiations with Valve to gain access to the GoldSrc engine around 2010 and to have Valve change some of the numerical limits originally imposed in the engine's use in Half-Life that would enable them to improve Sven Co-op.
Sources: en.wikipedia.org
==== Nucleic acid-based molecules ==== Nanogels are advantageous carriers of small, nucleic-acid based molecules that can be employed to treat a variety of diseases. Examples of three different types of molecules that fall into this category, oligonucleotides, miRNA, and nucleoside analogs, are discussed here. In one study, cationic synthetic nanogels modified with insulin and transferrin were synthesized to transport oligonucleotides, a possible therapeutic and diagnostic tool for neurodegenerative disorders, to the brain. These nanogels successfully localized through an in vitro model of the blood-brain barrier and accumulated in the brain in a mouse model. With the treatment of cardiovascular diseases in mind, polysaccharide-based nanogels have been functionalized with fucoidan to target overexpressed P-selectin receptors on platelets and endothelial cells. After loading with miRNA, these nanogels bound to platelets and became internalized by an endothelial cell line. Nanogels have also been used to encapsulate phosphorylated nucleoside analogs, or active forms of anticancer therapeutics. In one study, nanogels loaded with nucleoside 5'-triphosphates underwent surface modifications and successfully bound to overexpressed folate receptors on breast cancer cells. These nanogels were then internalized by the cells and produced a significant increase in cytotoxicity compared to control groups.
=== Backing fabrics === In these cases, a backing fabric can be used. Backing fabrics must be durable and able to withstand tensioned in order to offer support, but not so heavy that it causes strain on the original textile. The fabric should extend beyond the damaged areas in combination with appropriate stitching in weak areas when used in combination with local repairs and visual compensation techniques.
Tánaiste Micheál Martin announces Irish government plans to "initiate an inter-State case against the United Kingdom under the European Convention on Human Rights" over provisions in the Northern Ireland Troubles (Legacy and Reconciliation) Act 2023 which offers immunity from prosecution for certain Troubles-era related offences. Junior doctors in England begin another three-day strike over their long-running pay dispute. A number of ballet dancers are reported to have come forward to make claims about incidents of "body shaming" at UK ballet schools following a BBC investigation into the subject earlier in the year. COVID-19 in the UK: JN.1 is reported as a new variant of interest, following a recent, rapid rise in COVID-19 cases. A teenage boy and girl who shared an obsession with violence and torture are convicted of the murder of Brianna Ghey. Lawrence Bierton is sentenced to a whole life order for the murder of his neighbour, 73-year-old Pauline Quinn, who he battered to death with a coffee table while out on parole following his conviction for two previous murders in 1996. The Scottish Government confirms it will abandon its legal challenge against the UK government's veto of the Gender Recognition Reform (Scotland) Bill. Eight-year-old girl, Bodhana Sivanandan from Harrow, London is crowned best female player at the European blitz chess championships in Zagreb, Croatia. The three men convicted of attempted murder for shooting two children on 14 December are jailed for 23 years.
=== Human plasma proteome === Characterizing the human plasma proteome has become a major goal in the proteomics arena, but it is also the most challenging proteomes of all human tissues. It contains immunoglobulin, cytokines, protein hormones, and secreted proteins indicative of infection on top of resident, hemostatic proteins. It also contains tissue leakage proteins due to the blood circulation through different tissues in the body. The blood thus contains information on the physiological state of all tissues and, combined with its accessibility, makes the blood proteome invaluable for medical purposes. It is thought that characterizing the proteome of blood plasma is a daunting challenge. The depth of the plasma proteome encompasses a dynamic range of more than 1010 between the highest abundant protein (albumin) and the lowest (some cytokines) and is thought to be one of the main challenges for proteomics. Temporal and spatial dynamics further complicate the study of human plasma proteome. The turnover of some proteins is quite faster than others and the protein content of an artery may substantially vary from that of a vein. All these differences make even the simplest proteomic task of cataloging the proteome seem out of reach. To tackle this problem, priorities need to be established. Capturing the most meaningful subset of proteins among the entire proteome to generate a diagnostic tool is one such priority. Secondly, since cancer is associated with enhanced glycosylation of proteins, methods that focus on this part of proteins will also be useful.
Sources: en.wikipedia.org
=== Diversification and decline === The ensuing financial crisis prompted a major strategic transition. In 1970, HVEC's losses represented 31 percent of total stockholder investment. The company laid off 100 employees and suspended many research programs, citing insufficient federal funding for basic physics research. That year also marked a leadership transition: Pascal Levesque, head of the profitable HVEC subsidiary Electronized Chemicals Corporation, became president and chief executive, while departing president Denis Robinson assumed the chairmanship held by Trump. Under new management, HVEC diversified into industrial applications of its accelerator technologies. By 1972, the company had reorganized as a miniconglomerate with more than ten subsidiaries manufacturing plastics, power equipment, and radiation processing systems—products enabled by particle accelerators rather than particle accelerators themselves. The diversification strategy yielded several commercially successful products. Electronized Chemicals Corporation's heat-shrink tubing, made by electron-beam crosslinking of polyethylene, became ubiquitous in electrical wiring. The technology enabled modern wire harnesses in automobiles and aircraft, where compact, reliable insulation was essential. Ion Physics Corporation introduced radiation-based ion implantation, enabling precise control of transistor characteristics in integrated circuits. HVEC closed Ion Physics in 1971, but became standard practice throughout the global semiconductor industry by the late 1970s.
Following the approval of eteplirsen, two other drugs of a similar kind, golodirsen and viltolarsen received provisional approval from the FDA for the treatment of people with a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping as well as casimersen for exon 45 skipping.
His work has also examined the changing role of behavioral treatment when used with GLP-1 medications, as well as the psychiatric safety of the new drugs. With colleague Gary Foster, Wadden developed the Weight and Lifestyle Inventory (WALI), a widely used self-report tool for obesity assessment, including in bariatric surgery programs. He has published more than 500 refereed papers and 40 book chapters, and co-edited seven books, including Handbook of Obesity Treatment. Since 2020, he has been recognized by Clarivate as a Highly Cited Researcher across multiple fields.
Includes the perirhinal and entorhinal cortices. Rhombencephalon Also known as the hindbrain, this embryonic brain region gives rise to the pons, medulla oblongata, and cerebellum. Ribosome A cellular organelle responsible for protein synthesis. In neurons, local ribosome activity occurs in dendrites and axons, supporting synaptic plasticity. Rostral A directional term meaning “toward the nose” or front of the brain. Often used in anatomical descriptions of the central nervous system. Ruffini ending A slow-adapting mechanoreceptor found in the skin that detects skin stretch and contributes to proprioception and object manipulation. RUNX1 A transcription factor involved in sensory neuron differentiation and pain signaling. Active during embryonic development and in peripheral nervous system patterning.
In 1966, he and other musicians from the Boston folk scene formed a group called the International Submarine Band. In 1967, after briefly residing in the Kingsbridge section of the Bronx, they moved to Los Angeles. Following several lineup changes, the band signed with Lee Hazlewood's LHI Records, where they spent late 1967 recording Safe at Home. The album contains one of Parsons' best-known songs, "Luxury Liner", and an early version of "Do You Know How It Feels," which he revised later in his career. Safe at Home would remain unreleased until mid-1968, by which time the International Submarine Band had broken up. The International Submarine Band appeared in the Peter Fonda film The Trip (1967) as a performing band in one of the clubs. Their song "Lazy Days" was offered for the film's soundtrack, but the soundtrack was done by Mike Bloomfield's Electric Flag. In 1967, Peter Fonda recorded a version of Parsons' song "November Nights" titled "November Night". The song was released as a single in March 1967, with Donovan's "Catch the Wind" on the B side.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.